Novel orally bioavailable γ-secretase inhibitors with excellent in vivo activity

Journal of Medicinal Chemistry

Volumn 52, Issue 11, 2009, Pages 3441-3444

  Keown, Linda E ^a   Collins, Ian ^a   Cooper, Laura C ^a   Harrison, Timothy ^a   Madin, Andrew ^a   Mistry, Jayesh ^a   Reilly, Michael ^a   Shaimi, Mohamed ^b   Welch, Christopher J ^b   Clarke, Earl E ^a   Lewis, Huw D ^a   Wrigley, Jonathan D J ^a   Best, Jonathan D ^a   Murray, Fraser ^a   Shearman, Mark S ^a  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',3',4',5,5',6,7,8,9,10 DECAHYDRO 2 [5 (4 FLUOROPHENYL) 1 METHYLPYRAZOL 3 YL] 5' (2,2,2 TRIFLUOROETHYL)SPIRO[6,9 METHANOBENZOCYCLOOCTENE 11,3' [1,2,5]THIADIAZOLE] 1',1' DIOXIDE; AMYLOID BETA PROTEIN; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG SYNTHESIS; ENZYME INHIBITION; IC 50; MOUSE; NONHUMAN; RAT; REACTION ANALYSIS; RHESUS MONKEY; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CYCLOOCTANES; INHIBITORY CONCENTRATION 50; MICE; PROTEASE INHIBITORS; THIADIAZOLES;

EID: 66749130196     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900056p     Document Type: Article

References (14)

1. Cummings, J. L. Alzheimer's disease. N. Engl. J. Med. 2004, 351, 56-67.
2. Hardy, J.; Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297, 353-356. (Pubitemid 34790756)
3. Ghosh, A. K.; Kumaragurubaran, N.; Hong, L.; Koelsh, G.; Tang, J. Memapsin 2 (β-secretase) inhibitors: drug development. Curr. Alzheimer Res. 2008 Apr, 5 (2), 121-131.
4. Harrison, T.; Churcher, I.; Beher, D. γ-Secretase as a target for drug intervention in Alzheimer's disease. Curr. Opin. Drug Discovery Dev. 2004, 7, 709-719. (Pubitemid 39329873)
5. Lewis, S. J.; Smith, A. L.; Neduvelil, J. G.; Stevenson, G. I.; Lindon, M. J.; Jones, A. B.; Shearman, M. S.; Beher, D.; Clarke, E.; Best, J. D.; Peachey, J. E.; Harrison, T.; Castro, J. L. A novel series of potent γ-secretase inhibitors based on a benzobicyclo[4.2.1]nonane core. Bioorg. Med. Chem. Lett. 2005, 15, 373-378. (Pubitemid 39647153)
6. Sparey, T.; Beher, D.; Best, J.; Biba, M.; Castro, J. L.; Clarke, E.; Hannam, J.; Harrison, T.; Lewis, H.; Madin, A.; Shearman, M.; Sohal, B.; Tsou, N.; Welch, C.; Wrigley, J. Cyclic sulfamide γ-secretase inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 4212-4216. (Pubitemid 41187988)
7. Clarke, E. E.; Shearman, M. S. Quantitation of amyloid-β peptides in biological milieu using a novel homogeneous time-resolved fluorescence (HTRF) assay. J. Neurosci. Methods 2000, 102, 61-68.
8. Lamb, B. T.; Sisodia, S. S.; Lawler, A. M.; Slunt, H. H.; Kitt, C. A.; Kearns, W. G.; Pearson, P. L.; Price, D. L.; Gearhart, J. D. Introduction and expression of the 400 kilobase amyloid precursor protein gene in transgenic mice. Nat. Genet. 1993, 5, 22-30. (Pubitemid 23261513)
9. For chromatography conditions, see Supporting Information.
10. Fedorov, A. Y.; Finet, J.-P. N-Phenylation of azole derivatives by triphenylbismuth derivatives/cupric acetate. Tetrahedron Lett. 1999, 40, 2747-2748. (Pubitemid 29145051)
11. Combes, S.; Finet, J.-P. A convenient synthesis of triarylbismuth diacetates. Synth. Commun. 1996, 26, 4569-4575. (Pubitemid 26423497)
12. Collman, J. P.; Zhong, M. An efficient diamine·copper complex-catalysed coupling of arylboronic acids with imidazoles. Org. Lett. 2000, 2, 1233-1236.
13. Bourrain, S.; Ridgill, M.; Collins, I. Regioselective rapid analogue syntheses of 1-methyl-3,5-diarylpyrazoles via palladium-catalysed coupling to 3(5)-pyrazolyl nonaflates. Synlett 2004, 5, 795-798. (Pubitemid 38496896)
14. Lewis, H. D.; Perez Revuelta, B. I.; Nadin, A.; Neduvelil, J. G.; Harrison, T.; Pollack, S. J.; Shearman, M. S. Catalytic site-directed γ-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and β-APP cleavages. Biochemistry 2003, 42, 7580-7586. (Pubitemid 36735835)